DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1990)

Axial Spondyloarthritis | Current Treatment | Detailed, Expanded Analysis: Ankylosing Spondylitis: Treatment Algorithms: Claims Data Analysis

Axial Spondyloarthritis | Current Treatment | Detailed, Expanded Analysis: Ankylosing Spondylitis: Treatment Algorithms: Claims Data Analysis

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

MARKET OUTLOOK

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals for AS include improving signs and symptoms of the disease, improving physical function, preventing disability, and slowing or preventing structural damage. TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia, and infliximab biosimilars) have demonstrated efficacy in reducing disease activity in AS. All approved agents in this class are perceived as highly effective options for patients who require more-potent therapies beyond first-line nonsteroidal anti-inflammatory drugs (NSAIDs). Novartis’s IL-17 inhibitor Cosentyx offers an alternative mechanism of action as the only approved non-TNF biological therapy for AS.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AS patients?
  • How has Cosentyx been integrated into the treatment algorithm?
  • What percentage of AS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of AS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States.

Key drugs:  Humira, Enbrel, Remicade, Simponi, Cimzia, Cosentyx, Vimovo, methotrexate.

Table of contents

  • Detailed, Expanded Analysis: Ankylosing Spondylitis: Treatment Algorithms: Claims Data Analysis
    • Treatment Algorithms Ankylosing Spondylitis US February 2019

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Maria Genco, Ph.D
  • Maria Genco, is an analyst on the Immune and Inflammatory Disorders group at Decision Resources Group, primarily focusing on rheumatoid arthritis and axial spondyloarthritis. She has authored market research reports on the RA disease landscape and commercial outlook of drugs, unmet needs in RA, and market access and reimbursement for RA targeted therapies. Prior to joining Decision Resources, Dr. Genco received her and in neuroscience from Brandeis University and a in neuroscience from Wellesley College.

Purchase Report

Recent reports:
You may also be interested in: